Evidence map›Paper›PMID 34312619›Full record

ArticleResearch square2021

Identification of the first COVID-19 infections in the US using a retrospective analysis.

David García-García, Enrique Morales, Cesar de la Fuente-Nunez, Isabel Vigo, Eva S Fonfría, Cesar Bordehore

Abstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

David García-GarcíaUniversity of Alicante: Universitat d'Alacant.
Enrique MoralesUniversity of Alicante: Universitat d'Alacant.
Cesar de la Fuente-NunezUniversity of Pennsylvania Department of Bioengineering.
Isabel VigoUniversity of Alicante: Universitat d'Alacant.
Eva S FonfríaUniversity of Alicante: Universitat d'Alacant.
Cesar BordehoreUniversity of Alicante: Universitat d'Alacant.ORCID 0000-0002-2816-0538

Funding

Combining chemical and computational tools for predictive models of microbiome communitiesR35GM138201 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DE LA FUENTE, CESAR · 2020 to 2024
$1.8M
NIGMS NIH HHS R35 GM138201
6 · The paper itself

Abstract

Accurate detection of early COVID-19 cases is crucial to drastically reduce infection, hospitalization, and death rates. However, it remains a challenge and methods for identifying initial COVID-19 cases are urgently needed. Here, we used the results from a seroprevalence study in 50 US states to apply our Retrospective Methodology to Estimate Daily Infections from Deaths (REMEDID) with the aim of analyzing the initial stages and spread of SARS-CoV-2 infections across the United States (US). Our retrospective data analysis revealed that the virus likely entered the country through California on December 28, 2019, which corresponds to 16 days before the officially recognized entry date established by the CDC. Thus, REMEDID provides evidence that SARS-CoV-2 entered the U.S. earlier than previously reflected in official data. Collectively, our mathematical modeling more accurately estimates the initial COVID-19 cases in the US, may be extrapolated to other countries, and may be used to retrospectively track the progress of the pandemic. Approaches such as REMEDID may enable health authorities to accelerate preventative measures aimed at controlling pandemics within weeks of their onset.

Identifiers

PMID34312619
PMCPMC8312904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.